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P2X receptors are a distinct family of ATP-gated ion channels with a number of physiological roles
ranging from smooth muscle contractility to the regulation of blood clotting. In this study we determined
whether the UV light-reactive ATP analogues 2-azido ATP, ATP azidoanilide (ATP-AA) and 20 ,30-O-(4-
benzoylbenzoyl)-ATP (BzATP) can be used to label the ATP binding site of P2X1 receptors. These ana-
logues were agonists, and in patch clamp studies evoked inward currents from HEK293 cells stably
expressing the P2X1 receptor. Following irradiation in the presence of these compounds subsequent
responses to an EC50 concentration of ATP were reduced by >65%. These effects were partially reversed
by co-application of ATP or suramin with the photo-reactive ATP analogue at the time of irradiation. In
autoradiographic studies radiolabelled 2-azido [g32P] ATP and ATP-AA-[g32P] cross-linked to P2X1 re-
ceptors and this binding was reduced by co-incubation with ATP. These studies demonstrate that photo-
reactive ATP analogues can be used to label P2X receptor and may prove useful in elucidating the ATP
binding site at this novel class of ATP binding proteins.
 2008 Elsevier Ltd. Open access under CC BY license.1. Introduction
The physiological effects of ATP are mediated through the acti-
vation of ionotropic P2X receptors and G-protein coupled P2Y
receptors (Burnstock, 2006; North, 2002). Seven P2X receptor sub-
units (P2X1–P2X7) have been identiﬁed and these associate to-
gether to form homo- or hetero-trimeric receptors with a range of
phenotypes (North, 2002; Roberts et al., 2006). The P2X receptor
membrane topology features two transmembrane-spanning seg-
ments, an extracellular loop and amino and carboxy termini which
exist intracellularly. P2Xreceptorshavebeen implicated inanumber
of physiological roles including regulation of blood clotting, smooth
muscle contractility, as well as pain and accordingly P2X receptors
arepotential targets forpharmacological intervention (Roberts et al.,
2006). The production of various pharmaceutical therapies by
rational drug design has been hindered because the extracellular
domain of P2X receptors contains a distinct ATP binding site that has
yet to be fully elucidated. One of the complications is the lack of
sequencehomologywith otherATPbindingprotein classes, i.e. none
of the ‘‘classical’’ nucleotide binding motifs have been detected inx: þ44 116 252 5045.
of St Andrews, St. Andrews,
Y license.P2X receptors. For example the motif GXXXXGKT/S (where X¼ any
residue), more commonly known as the Walker motif A (Walker
et al., 1982) is not present. Site-directed mutagenesis of conserved
amino acid residues in the extracellular loop and the structural
homology to other nucleotide binding proteins have been used to
proposedifferentmodels of theATPbinding site (Evans, inpress;Yan
et al., 2005). Although mutagenesis is a powerful tool in directing
attention to speciﬁc residues that appear to inﬂuence ATP potency,
discrimination between residues involved in agonist binding and
residues involved in the process of gating is difﬁcult.
Direct binding evidence can corroborate data from previous
studies as well as indicate other residueswhichmay play important
roles in the ATP binding site. Radiolabelled ATP analogues such as
50-(p-ﬂuorosulfonyl)benzoyladenosine (FSBA) have been used to
afﬁnity label a range of ATP binding proteins (e.g. Figures et al.,
1987). Similarly photo-reactive ATP analogues have been used to
identify residues within the binding sites of many proteins in-
cluding the Naþ,Kþ-ATPase (Tran et al., 1994), KATP channels
(Tanabe et al., 2000) and natriuretic peptide receptor (Joubert et al.,
2005). The identiﬁcation of a photo-reactive or cross-linking
compound with activity at P2X receptors would be the ﬁrst step in
providing direct evidence of the identity of some of the amino acid
residues which contribute to the ATP binding site, therefore we
investigated whether FSBA, 2-azido ATP, ATP azidoanilide or 20,
30-O-(4-benzoylbenzoyl)-ATP (BzATP) can be used to label the P2X
receptor binding site.
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2.1. Cell culture
Native HEK293 and HEK293 cells which stably express the human P2X1 receptor
or the human P2X4 receptorwere cultured as previously described (Vial et al., 2004).
Native HEK293 cells, at 80–90% conﬂuence, were plated onto 40 mm cell culture
dishes. For each dish of cells, transient transfection was conducted using 1 mg DNA
(rat P2X2 and rat P2X3) and 10 ml lipofectamine 2000 (Invitrogen) in 500 ml of se-
rum-free Opti-MEM1. To conﬁrm the presence of transfected protein, GFP (green
ﬂuorescent protein) was co-transfected. After 6–10 h incubation, cells were plated
onto 13 mm coverslips and left to grow in DMEM cell culture medium. Cells were
subjected to experiments 24–48 h after transfection. Single cells that expressed
green ﬂuorescence implied expression of the transfected gene (P2X2 or P2X3) and
were subjected to electrophysiological recording. The preparation of plates, cell
culture and transfection all took place in a laminar ﬂow hood under sterile
conditions.
2.2. Electrophysiological recordings
Electrophysiological recordings were made using the whole cell patch clamp
conﬁguration on single cells at room temperature (21–26 C). Microelectrodes were
ﬁlled with internal solution composed (in mM) of K gluconate,140; EGTA,10; HEPES,
10; NaCl, 5 (pH 7.3, adjusted with KOH) and had resistances in the range of 2–6 MU.
The bath was continuously perfused with extracellular solution containing (in mM)
NaCl, 150; HEPES, 10; glucose, 11; KCl, 2.5; MgCl2, 1; CaCl2, 2.5 (pH 7.3, adjusted with
NaOH). Cells were voltage clamped at 70 mV (after correction for the tip potential)
and the data was low pass-ﬁltered at 1 kHz and digitized at a sampling interval of
200 ms. Using an Axopatch 200B ampliﬁer, data was collected with pClamp 8.1/9.0
software. Agonists were applied for 1 s via a fast-ﬂow U-tube (Evans and Kennedy,
1994) and P2X1 receptor responses were quantiﬁed by measuring the peak current
amplitude relative to the base-line holding current immediately preceding agonist
application.
2.3. Cross-linking with photo-reactive ATP analogues
Wild-type P2X1 cells, mounted on 13 mm coverslips, were placed in an 8.8 cm2
petri dish (Nunclon, UK) and were incubated in the presence of 2 ml of 30 mM
2-azido ATP, 100 mMATP azidoanilide (both Afﬁnity Labelling Technologies Inc, USA)
or 10 mM BzATP (Sigma, UK). A UV light source (Uvitech, UK, LF206.MS; Flowgen,
Ashby Park, Leicestershire, UK) was housed in a box which was maintained at room
temperature and constant humidity and excluded outside light. The cells were
placed 7.5 cm from the UV light source and the wavelength was set at 312 nm. Cells
were then continually irradiated for 3 min. After irradiation, cells were washed for
5 min in extracellular solution and were ready for electrophysiological recording.
2.4. Radiolabelled cross-linking
To detect the binding of 2-azido ATP or ATP azidoanilide to the P2X1 receptor,
native HEK293 cells and wild-type P2X1 cells were cultured in 24-well plates in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco) with Earle’s salts, glutamax 1,
10% foetal calf serum and 1% non-essential amino acids. Wild-type P2X1 cells were
maintained under permanent selection in 600 mg/ml G418 (Invitrogen). When cells
reached 80% conﬂuence the growth media was removed and replaced with either
1 mM 2-azido [g32P] ATP (0.32 MBq) or 1 mM ATP-AA-[g32P] (0.92 MBq) (both
Afﬁnity Labelling Technologies Inc, USA) at 0.5 ml/well. The 24-well plate containing
these cells was placed in the UV box and continually irradiated by 312 nm of UV light
for 3 min. The 24-well plate was placed on ice and unbound 32P labelled ATP ana-
logue was removed by washing the cells twice with 1 ml PBS. The cells were then
lysed into a homogenising buffer (100 ml) containing 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 40 mM Tris–HCl (pH7.4), 8 mM Tris–base, 1% triton X and a mixture of
protease inhibitors (1:100 dilution) (Sigma). The cell homogenate was centrifuged
for 5 min at 13,000 rpm (4 C) on a benchtop centrifuge, the cell debris was dis-
carded and the supernatant was stored on ice. A stock solution of P2X1 antibody
(0.3 mg/ml) (Alomone, Israel) was prepared and 3 ml of the solution was added to
85 ml of the supernatant. The mixture was allowed to incubate on ice for 1 h. Protein
A-sepharose beads (30 mg/ml) (Amersham, UK) were pre-washed in PBS and the
resultant antibody–antigen complex was precipitated with the addition of 75 ml
protein A-sepharose beads and rolled at 4 C overnight. One millilitre of homoge-
nising buffer was added to the protein A-sepharose beads (complexed with the
antibody and antigen) and the mixture was spun on a benchtop centrifuge at
13,000 rpm for 5 min. The supernatant was removed with a pump aspirator and
discarded. The process was repeated three times in total to enable the beads to be
washed of any unbound radioactive material. Twenty microlitres of sample buffer
(with 5% b-mercaptoethanol) were added to the protein A-sepharose P2X1 pellet.
The pellet was heated to 95 C for 5 min to allow the protein to elute from the beads.
Twenty microlitres of the sample were removed and loaded onto a 10% SDS-PAGE
gel and run at 120 V. For autoradiography, the gels were dried and exposed to X-ray
ﬁlm for 48–72 h at 80 C.2.5. Data analysis
The results are expressed as mean standard error of mean and analyzed using
the appropriate Student’s t-test. Data analysis was carried out with the computer
package, ‘‘Excel’’ and the graphics package ‘‘Origin 6’’ was used to construct the
graphs.3. Results
3.1. Effects of the chemical cross-linking compound FSBA
The ATP analogue FSBA is a chemical cross-linking compound.
FSBA (100 mM) had no agonist action at hP2X1 receptors stably
expressed in HEK293 cells. Similarly following 1 h incubation with
FSBA (a commonly used procedure to cross-link and block ATP
binding sites) subsequent responses to 1 mM ATP (an wEC50 con-
centration) were no different to those recorded under control con-
ditions (control peak amplitude 2.84 0.28 and 2.76 0.42 nA
for control and following FSBA treatment, respectively, n¼ 10.6).
These results show that FSBA is ineffective as an agonist or cross-
linker at the P2X1 receptor.
3.2. 2-Azido ATP is an agonist at human P2X1 receptors
2-Azido ATP has a reactive group substituted at the 2nd position
on the adenine ring of ATP and may be useful for investigating
amino acid residues close to the site of the adenine ring of ATP
bound to P2X receptors. 2-Azido ATP evoked concentration de-
pendent desensitizing inward currents at P2X1 receptors with an
EC50 ofw3 mM. This suggests that 2-azido ATP may be suitable for
cross-linking to P2X receptors following UV illumination (Fig. 1).3.3. The effects of UV irradiation of 2-azido ATP on
P2X1 receptor currents
The photo-active azido group, upon UV irradiation, is converted
into a highly reactive nitrene that can form covalent bonds that
could be used to cross-link the compound to the P2X1 receptor. As
a control, cells were UV irradiated for 3 min. They were then placed
on the electrophysiology rig and application of 1 mM ATP elicited
responses of 3.03 0.57 nA (n¼ 6); this was not signiﬁcantly
different from untreated control cells (3.47 0.9 nA (n¼ 9)) and
indicates that this UV irradiation protocol has no effect on the
sensitivity of P2X1 receptors.
To test whether 2-azido ATP could cross-link to the receptors,
cells were treated in 30 mM 2-azido ATP (a maximal agonist con-
centration) and UV irradiated for 3 min. The cells were then placed
in the electrophysiology recording chamber and perfused. Whole
cell patch clamp recordings were made from cells over a 45 min
period. Results showed that the response produced by 1 mM ATP
application was reduced by 86% to 0.49 0.09 nA (n¼ 30) a de-
crease from 3.47 0.9 nA (n¼ 9) which was recorded from cells
which had not been UV irradiated (Fig. 2). This reduction in ATP
responsiveness suggested cross-linking of the compound to the
receptor binding site. As a control, cells were pre-treated in 30 mM
2-azido ATP (without UV irradiation) and the responses were
recorded over a 45 min time period. Within 1–5 min the responses
were signiﬁcantly reduced to 0.710.35 nA (n¼ 10). However,
this reduction results most likely from the time required for P2X1
receptors to recover from desensitisation as the peak amplitude
responses recover after continual wash with extracellular solution.
Within 30–45 min the responses from cells pre-treated in 30 mM
2-azido ATP increased to 3.8 0.26 nA (n¼ 10). These results
suggest that the reduction in response brought about by the UV
irradiation of cells in the presence of 2-azido ATP was caused by the
cross-linking of 2-azido ATP within the P2X1 ATP binding domain.
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Fig. 1. The agonist action of 2-azido ATP. (A) Whole cell patch clamp traces in response
to agonists. ATP evoked a desensitizing, inward current (application of 1 mM ATP is
indicated by black bar). The application of 2-azido ATP (indicated by the open bars)
produced a similar desensitizing inward current that increased when the applied
concentration of 2-azido ATP was increased. (B) Concentration–response curves to ATP
and 2-azido ATP. Error bars indicate SEM.
UV
Irradiated
1 –5mins wash
ATP
(1µM) 
UV
Irradiated
Pre-treated
30µM 2-azido ATP
A
B
30 – 45mins wash
Pre-treated
30µM 2-azido ATP
 
Pre-treatment with 2-azido 
ATP
Pre-treatment with 2-azido 
ATP and UV irradiation 
C
1 – 5mins wash 30 – 45mins wash
* * *
A
m
p
l
i
t
u
d
e
 
o
f
 
t
h
e
 
I
n
w
a
r
d
 
C
u
r
r
e
n
t
 
(
n
A
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
* * *
* * *
2s
2nA
2s
2nA
Fig. 2. Effect of cross-linking 2-azido ATP to the P2X1 receptor. HEK293 cells which
stably expressed the P2X1 receptor were pre-treated in either 30 mM 2-azido ATP and
UV irradiated for 3 min or 30 mM 2-azido ATP (without UV irradiation). They were then
placed on the electrophysiology rig and were continually washed in extracellular so-
lution for the time described. ATP (1mM) was then applied (application indicated by
black bar). (A) Whole cell patch clamp traces recorded 1–5 min after washout of 2-
azido ATP (for representative cells) show the reduction in ATP response caused by
desensitisation of the P2X1 receptor. (B) Traces show the recovery of ATP evoked
currents in cells pre-treated with 2-azido ATP (without UV). The inhibited response of
cells pre-treated in 2-azido ATP and UV irradiated suggests cross-linking. (C) Pooled
data shows the effects of each scenario (*p< 0.05, **p< 0.01 and ***p< 0.001 show
signiﬁcant difference from the control). Error bars indicate SEM.
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To further test 2-azido ATP’s validity as a cross-linking com-
pound at the P2X1 receptor, receptor protection experiments were
conducted. The P2 receptor antagonist suramin (100 mM), or
a supramaximal concentration of ATP (300 mM), was used to pre-
treat the cells and then they were UV irradiated in the presence of
either ATP or suramin along with 30 mM 2-azido ATP. Cross-linking
by 2-azido ATP caused the subsequent peak current responses from
P2X1 cells to be reduced by 86% (see above). P2X1 receptors that
were treated in 300 mM ATP, prior to UV irradiation in the presence
of 30 mM 2-azido ATP were reduced, compared to controls, by 57%
to 1.58 0.48 nA (n¼ 12); a signiﬁcantly smaller reduction then
when treated with 2-azido ATP irradiation alone (p< 0.01). P2X1
receptors that were treated with 100 mM suramin, prior to and
during UV irradiation in the presence of 30 mM 2-azido were
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Fig. 3. The cross-linking effects of 2-azido ATP reduced by receptor protection with
excess ATP or suramin. (A) Representative currents evoked by ATP (1 mM) evoked from
HEK293 cells stably expressing the P2X1 receptor under control conditions, following
2-azido ATP and irradiation or pre-treated 300 mM ATP, 100 mM suramin or 300 mM
adenosine in addition to 30 mM 2-azido ATP and UV irradiated for 3 min. Patch clamp
traces show the reduction in inhibition by 2-azido ATP and UV irradiation caused by
protection of the P2X1 receptors by ATP or suramin. The addition of adenosine did not
protect the P2X1 receptors from the inhibitory effect of 2-azido ATP. (B) Summary data
from A of ATP (1 mM) evoked responses (**p< 0.01 and ***p< 0.001). Error bars in-
dicate SEM. (C) Samples of non-transfected HEK293 cells and HEK293 cells stably
expressing the P2X1 receptor were treated with 1 mM (0.32 MBq) 2-azido-[g32P] ATP.
In addition, cells stably expressing the P2X1 receptor were treated with 10 mM ATP and
1 mM 2-azido ATP. All samples were UV irradiated for 3 min. After lysis, samples were
immunoprecipitated with the P2X1 antibody (Alomone) and ran on a 10% SDS-PAGE
gel. After drying, the gel was exposed to autoradiography ﬁlm for 3 days at 80 C.
Intense bands appeared at a similar weight range for the glycosylated monomer
(w55 kDa) and dimer (w110 kDa) of P2X1 protein and suggest successful labelling by
2-azido ATP. 2-Azido treatment (1 mM) shows intense binding to the P2X1 receptor but,
as indicated in the electrophysiological study, this binding was reduced when the cells
were treated with ATP (10 mM).
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rents were only reduced by 13% to 3.2 0.42 nA compared to
controls (n¼ 23) (Fig. 3).
One possibility for the protection of the current response is that
the addition of ATP or suramin caused an increased absorbance of
UV light. This is called molar extinction. Molar extinction refers to
the potential absorbance of the UV light by the molecules of ATP or
suramin. If the light was absorbed by these molecules, then less
light would have been able to penetrate down to the P2X1 re-
ceptors themselves. To test this theory, 300 mM adenosine was
used. Adenosine has no pharmacological action at the P2X re-
ceptors and so should not provide protection from the effects of UV
irradiated 2-azido ATP. The level of inhibition following 2-azido ATP
irradiation was the same whether adenosine (300 mM) was present
or absent (reduction to 0.53 0.17 nA (n¼ 20, Fig. 3)). This shows
that the reduction in the effects of 2-azido ATP by suramin or ATP
do not result from a molar extinction effect and demonstrates that
2-azido ATP is acting at the ATP binding site on the P2X1 receptor
and could be used to label the P2X1 receptor. One consideration is
that reactive 2-azido ATP, and the other reactive analogues (see
later), may diffuse away from the ATP binding site following UV
irradiation and could react with nearby residues. However, in
studies on the Na,K-ATPase where 2-azido was used in a similar
way following peptide sequencing it was shown to cross-link to
a single residue within the ATP binding site (Tran et al., 1994)
suggesting that diffusion of the reactive compound away from the
binding site is not a major contaminating factor.3.5. Radiolabelling of P2X1 receptors with 2-azido [g32P] ATP
The cross-linking of 2-azido ATP and the P2X1 receptor was
tested using a radiolabelling assay. HEK293 cells stably expressing
the P2X1 receptor were treated with 1 mM (0.32 MBq) 2-azido
[g32P] ATP. To determine the level of non-speciﬁc binding, non-
transfected HEK293 cells were treated similarly. Both sets of cells
were UV irradiated and the cells were homogenised. To reduce non-
speciﬁc binding the cross-linked P2X1 receptor was isolated by
immunoprecipitation with the P2X1 antibody and the samples
were run on a 10% SDS gel. Exposure of the dried gel to autoradi-
ography ﬁlm produced intense bands which corresponded to the
sizes of the glycosylated P2X1 monomer (w55 kDa) and a small
amount of dimer (w110 kDa). The intensity of these bands was
markedly reduced when P2X1 cells were pre-treated with 10 mM
ATP (in addition to 2-azido ATP). This indicated that ATP protected
the receptors from cross-linking to 2-azido ATP by occupying the
majority of sites prior to UV irradiation (Fig. 3C) and suggests that
the majority of the photo-reactive compound does not bind ran-
domly to the P2X1 receptor just because of close proximity of the
compound at the time of irradiation. In conclusion this evidence
corroborates the ﬁndings made earlier and directly suggests that
ATP and 2-azido ATP compete for the same binding site on the P2X1
receptor. It conﬁrms the identiﬁcation of 2-azido ATP as a cross-
linking compound which directly binds to the P2X1 receptor.3.6. The effects of 2-azido ATP at other P2X receptor subtypes
Previous studies have shown that there are differences between
the pharmacology of the various subtypes of the P2X receptor. The
ability of 2-azido ATP to cross-link to particular P2X subtypes may
reﬂect differences in their respective ATP binding domains. In the
presence of 2-azido ATP, HEK293 cells expressing P2X2–P2X4 were
all UV irradiated for 3 min. Subsequent patch clamp recordings
monitored changes in the responses to their approximate EC50 ATP
concentrations (Fig. 4). ATP (1 mM) was used for P2X3 expressing
cells and 10 mMATP was used for P2X2 and P2X4 cells. ATP (at EC50
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Fig. 4. Cross-linking effect of 2-azido ATP at other P2X subtypes. HEK293 cells stably
expressing the human P2X4 receptor and cells transfected with rat P2X2 and rat P2X3
DNAwere subjected to similar experiments as those conducted at the P2X1 receptor. As
before, cells were treated in 30 mM 2-azido ATP and UV irradiated for 3 min and tested
with their respective EC50 concentration of ATP. (A)Whole cell patch clamp traces show
representative currents to ATP at EC50 concentration for different P2X subtypes under
control conditions and following UV irradiation in the presence of 2-azido ATP. (C)
Summary data shows the inhibition of responses to an EC50 concentration of ATP by UV
irradiation with 2-azido ATP (*p< 0.05 and ***p< 0.001). Error bars indicate SEM.
K.C. Agboh et al. / Neuropharmacology 56 (2009) 230–236234concentration of ATP) was applied to untreated P2X2–P2X4 cells as
a control.
At the P2X2 receptor 10 mM ATP application evoked inward
currents that slowly desensitised. The mean peak current was
2.3 0.45 nA (n¼ 5). Irradiation of these cells in the presence of
2-azido ATP caused the mean peak current to reduce to
0.46 0.07 nA (n¼ 18). This was an 80% reduction in the current
response (p< 0.001). The application of 1 mMATP at P2X3 receptors
caused transient inward currents that quickly desensitised. The
mean peak current was 2.12 0.38 nA (n¼ 5). At P2X3 receptorsthe mean peak current was reduced to 0.35 0.09 nA (n¼ 12),
a reduction of 83% (p< 0.001). The application of 10 mM ATP to
P2X4 receptors evoked transient inward currents that were slow to
desensitize. The mean peak current was 1.06 0.24 nA (n¼ 5).
The peak amplitude of the response was reduced to
0.58 0.13 nA (n¼ 9). This was a 45% reduction (p< 0.05). These
results suggest that 2-azido ATP can be used to cross-link a range of
P2X receptors.
3.7. Effects of ATP azidoanilide at P2X1 receptors
ATP azidoanilide (ATP-AA) has a substituted reactive azidoani-
lide moiety at the end of the gamma phosphate of ATP. ATP-AA
(1 mM) was ineffective as an agonist at P2X1 receptors, however,
responses were evoked at 100 mM (mean amplitude 2.10.4 nA,
n¼ 10). When cells expressing the P2X1 receptor were treated ATP-
AA (100 mM) and UV irradiated currents evoked by ATP (1 mM)were
reduced from a control in the absence of ATP-AA of 3.7 0.7 nA
(n¼ 10) by 67% to 1.2 0.4 nA (n¼ 30) (p< 0.01). This reduction
in P2X1 receptor current by UV treatment with ATP-AA was re-
duced signiﬁcantly (p< 0.01 for each) to 25 and 30% by co-appli-
cation of ATP (300 mM) or suramin (100 mM), respectively (Fig. 6).
These results suggest that ATP-AA directly cross-links to the ATP
binding site of the P2X1 receptor following UV irradiation. To test
this directly we determinedwhether radiolabelled ATP-AA could be
cross-linked to P2X1 receptors. Following ATP-AA-[g32P](1 mM)
treatment radioactivity associated with an w55 kDa protein was
recorded from HEK293 cells expressing the P2X1 receptor but not
non-transfected HEK293 control cells. The P2X1 receptor speciﬁc
labelling was reduced by>90% by co-applicationwith 10 mMATP at
the time of irradiation (Fig. 5). Taken together these results dem-
onstrate that ATP-AA can be used to cross-link to P2X1 receptors.
3.8. Effects of BzATP on P2X1 receptor currents
BzATP is an ATP analogue with substitutions on the ribose and
has been used to label the nucleotide binding site of P2Y receptors
(Erb et al., 1993). BzATP (10 mM, a maximal concentration; Roberts
and Evans, 2004) evoked P2X1 receptor currents (4.5 0.7 nA,
n¼ 14) of equivalent amplitude to an EC50 concentration of ATP
(1 mM, peak amplitude 3.7 0.4 nA, n¼ 5) consistent with its action
as a partial agonist at the P2X1 receptor (Roberts and Evans, 2004).
ATP (1 mM) evoked responses were reduced by 89% (to
0.5 0.1 nA, n¼ 52) following incubationwith BzATP (10 mM) and
UV irradiation (Fig. 6). BzATP treatment alone had no effect on ATP
evoked currents indicating that the reduction following UV irra-
diation results from BzATP cross-linking to the receptor locking the
receptor in a desensitised state. The inhibition by UV irradiation in
the presence of BzATP could be signiﬁcantly reduced by co-appli-
cation with either ATP (300 mM) or suramin (100 mM) to 61 and
23%, respectively (Fig. 6). These results suggest that the BzATP is
acting to cross-link to the P2X1 receptor at the ATP binding site.
4. Discussion
P2X receptors comprise a distinct family of ligand gated ion
channels and sequence analysis suggests that they have a novel
mechanism of ATP binding. In the absence of a solved structure for
the P2X receptor site-directed mutagenesis studies have been used
to identify regions of the receptor that are important for de-
termining ATP actions. Cross-linking of nucleotide analogues to
a variety of proteins has been useful in determining the site of ATP
binding. In this study we have shown that the photo-reactive
compounds 2-azio ATP, ATP-AA and BzATP (for structures see Fig. 7)
are agonists at the receptor and useful for the study of agonist
binding at P2X receptors. The reactive side groups of these
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Fig. 6. Effects of UV irradiation of BzATP on P2X1 receptor currents and protection by
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treating cells with either 300 mM ATP or 100 mM suramin reduced current inhibition by
BzATP (***p< 0.001 from UV irradiation with 10 mM BzATP alone).
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Summary data from A (**p< 0.01 and ***p< 0.001). Error bars indicate SEM. (C) Ra-
diolabelled binding studies with P2X1 protein. Non-transfected HEK293 (NT HEK) cells
and HEK293 cells stably expressing the P2X1 receptor were pre-treated in 1 mM
(0.92 MBq) ATP azidoanilide-[g32P]. In addition, cells stably expressing the P2X1 re-
ceptor were treated with 10 mM ATP and 1 mM azidoanilide. All samples were UV ir-
radiated for 3 min. After lysis, the protein was immunoprecipitated with the P2X1
antibody (Alomone) and ran on 10% SDS-PAGE. After drying, the gel was exposed to
autoradiography ﬁlm for 4 days at 80 C. Intense bands appear at a similar weight
range for the glycosylated monomer (w55 kDa) and dimer (w110 kDa) for the P2X1
protein and suggest successful labelling by ATP azidoanilide. ATP azidoanilide (1 mM)
treatment shows strong binding to the P2X1 receptor this binding was reduced when
ATP (10 mM) was co-applied.
K.C. Agboh et al. / Neuropharmacology 56 (2009) 230–236 235substituted ATP analogues cross-link to the P2X receptor at sites
that are likely to be close to those involved in ATP binding.
FSBA has adenosine and ribose moieties but does not have
a phosphate tail. In place of the ﬁrst phosphate group there is
a carbonyl group, the second phosphate is replaced by a benzene
ring and the terminal phosphate is replaces by a sulfonyl ﬂuoride
moiety. The reactive sulfonyl ﬂuoride group confers the ability of
FSBA to bind to a broad range of nucleotide binding sites. It has
a reactive sulfonyl ﬂuoride group that is an electrophilic agent incovalent reactions with several types of amino acids; these include
tyrosine, lysine, histidine, serine and cysteine (Colman, 1983). Nu-
cleotide binding sites as diverse as the ADP receptor on platelets
(Figures et al., 1987), the binding domain on the ArsA protein of E.
coli (Ramaswamy and Kaur, 1998) and the nucleotide binding site
on the enzyme pyruvate kinase (Wyatt and Colman, 1977) have
been successfully labelled with FSBA. However, in the present study
FSBAwas ineffective as an agonist or cross-linker at P2X1 receptors.
The lack of agonist action of FSBA and inability to block subsequent
ATP evoked responses shows that FSBA does not bind to the re-
ceptor and is consistent with the lack of effects of ADP as an agonist
or antagonist at the receptor and supports the concept that the P2X
receptor drugs need to have adenine, ribose and triphosphate
groups to be reactive. The lack of effect of FSBA also suggests once
again that the ATP binding site of P2X receptors is different from
those of many other ATP binding proteins.
2-Azido ATPwas effective as an agonist at the P2X1 receptor and
this is consistent with previous reports showing that 2-chloro and
2-methyl thio ATP (Evans et al., 1995) are agonists at the P2X1
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Fig. 7. Structures of reactive ATP analogues. (A) 2-Azido ATP. (B) ATP azidoanilide. (C)
20 ,30-O-(4-benzoylbenzoyl)-ATP.
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adenine ring are well tolerated. The binding of 2-azido ATP (and for
ATP-AA and BzATP) leads to activation and desensitisation of the
receptor. Thus it seems likely that following UV irradiation the 2-
azido ATP (and ATP-AA and BzATP) inhibits subsequent ATP re-
sponses by locking the receptor in an agonist bound desensitised
state. This also demonstrates that the agonist needs to unbind from
the receptor in order for recovery from desensitisation. The
blocking of the inhibitory actions of 2-azido ATP and UV irradiation
by application of ATP and suramin, as well as the radioligand
binding experiments supports that 2-azido ATP mediates its effects
following UV irradiation by acting at the ATP binding site. We have
used radiolabelled 2-azido ATP to study changes in agonist sensi-
tivity at P2X1 receptor mutants (Roberts and Evans, 2007). The
success of cross-linking 2-azido ATP was not restricted to the P2X1
receptor; ATP responses at P2X2–P2X4 receptors were also signif-
icantly inhibited when they were UV irradiated in the presence of
2-azido ATP. This suggests that such a radiolabelling assay may also
be useful for these other P2X receptor subtypes.
ATP-AA was an agonist at the P2X1 receptor, and following UV
irradiation could be cross-linked to the receptor agonist binding
site as assessed by the reduction of subsequent ATP responses or
the incorporation of the radiolabelled agonist. This shows that
substitutions at the end of the phosphate tail are well tolerated as
has been shown in previous studies using for example diadenosine
pentaphosphate (for review see Evans, in press). This suggests thatthe agonist binding pocket for the terminal phosphate is somewhat
open-ended so that it can tolerate/incorporate the substitutions.
BzATP is a partial agonist at the P2X1 receptor indicating that
the binding energy associated with ligand recognition is not sufﬁ-
cient to fully activate the receptor. The substitution of the benzoyl
group off the ribose suggests that this part of the ATPmolecule does
not form close contact with the receptor, indicating that this part of
the molecule may be on the periphery of the ATP binding site. The
ability of BzATP, following UV irradiation, to block subsequent ATP
evoked responses demonstrates that the benzoyl group can form
close contact and cross-link to the P2X1 receptor.
In summary we have shown that photo-reactive ATP analogues
with substitutions on the adenine ring, ribose and phosphate tail
can be cross-linked to the P2X1 receptor. This may prove useful for
providing direct evidence for the local environment of ATP binding
at the family of P2X receptors.
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